KYAN 001
Alternative Names: KYAN-001Latest Information Update: 12 Oct 2020
At a glance
- Originator Georgetown University
- Developer KYAN Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action HDAC4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Sep 2020 KYAN Therapeutics and Georgetown University entered a licensing agreement for the development of KYAN 001
- 25 Sep 2020 Preclinical trials in Cancer in Singapore (unspecified route) prior to September 2020
- 25 Sep 2020 Preclinical trials in Cancer in USA (unspecified route) prior to September 2020